Gefitinib is supplied in 250 mg tablets; the recommended daily dose being 250 mg once daily, with or without food. The elimination half-life is 48 hours and the mean bioavailability is 60%.

Mok and colleagues hypothesized that first-line therapy with the EGFR inhibitor gefitinib would be at least as efficacious as carboplatin–paclitaxel chemotherapy in former smokers and light ...